Predicting meningioma recurrence

Clinical Oncology

Volumn 11, Issue 6, 1999, Pages 398-404

  Hunt, D P J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MINICHROMOSOME MAINTENANCE PROTEIN; UNCLASSIFIED DRUG;

CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MENINGIOMA; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SURGICAL RISK; SURVIVAL;

EID: 0033396376     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.1999.9091     Document Type: Review

References (24)

1. Sacks O. An anthropologist on mars. 1995;Picador, London: p. 39-72.
2. .East Anglia Cancer Registry; Cancer incidence in East Anglia 1996; Cambridge; Quayside Press, 1998.
3. Wilson C B. Meningiomas: genetics, malignancy, and the role of radiation in induction and treatment. J Neurosurg. 81:1994;666-675.
4. Adegbite A B, Khan M I, Paine K W. The recurrence of intracranial meningiomas after surgical treatment. J Neurosurg. 58:1983;51-56.
5. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 20:1957;22-39.
6. Stafford S L, Perry A, Suman V J. Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc. 73:1998;936-942.
7. Hsu D W, Pardo F S, Efird J T. Prognostic significance of proliferative indices of meningiomas. J Neuropathol Exp Neurol. 53:1994;247-255.
8. Kunishio K, Ohmoto T. The significance of nucleolar organizer region (AgNOR) score in predicting meningioma recurrence. Cancer. 73:1994;2200-2205.
9. Dinda A K, Kharbanda K, Sarjar C. In-vivo proliferative potential of primary human brain tumours; its correlation with histological classification and morphological features: II. Non-glial tumors. Pathology. 25:1993;10-14.
10. Shibuya M, Hoshino T, Ito S. Meningiomas: clinical implications of a high proliferative potential determined by bromodeoxyuridine labelling. Neurosurgery. 30:1992;494-497.
11. Cobb M A, Husain M, Anderson B J. Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma. J Neurosurg. 84:1996;85-90.
12. Kakinuma K, Tanaka R, Onda K. Proliferative potential of recurrent intracranial meningiomas as evaluated by labelling indices of BUdR and Ki-67, and tumour doubling time. Acta Neurochir (Wien). 140:1998;26-31.
13. Karamitopoulou E, Perentes E, Tolnay M. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas. Hum Pathol. 29:1998;140-145.
14. Matsuno A, Nagashima T, Matsuura R. Correlation between MIB-1 staining index and the immunoreactivity of p53 protein in recurrent and non-recurrent meningiomas. Am J Clin Pathol. 106:1996;776-781.
15. Moller M L, Braendstrup O. No prediction of recurrence of meningiomas by PCNA and Ki-67 immunohistochemistry. J Neurooncol. 34:1997;241-246.
16. Nakabayashi H, Sakaguchi M, Katsuyama J. Proliferating potential of meningiomas evaluated by proliferating cell nuclear antigen expression. J Neurooncol. 24:1995;209-217.
17. Takeuchi H, Kubota T, Kabuto M. Prediction of recurrence in histologically benign meningiomas: proliferating cell nuclear antigen and Ki-67 immunohistochemical study. Surg Neurol. 48:1997;494-500.
18. Williams G H, Romanowski P, Morris L. Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. Proc Natl Acad Sci USA. 95:1998;14932-14937.
19. Newlon C S. Putting it all together: building a prereplicative complex. Cell. 91:1997;717-720.
20. .Romanowski, P, Madine, M, A. Trends Cell Biol1997;7:9-10.
21. Romanowski P, Madine M A, Laskey R A. XMCM7, a novel member of the Xenopus MCM family, interacts with XMCM3 and colocalizes with it throughout replication. Proc Natl Acad Sci USA. 93:1996;10189-10194.
22. Stillman B. Cell cycle control of DNA replication. Science. 274:1996;1659-1664.
23. Hiraiwa A, Jujita M, Nagasaka T. Immunolocalization of hCDC47 protein in normal and neoplastic human tissues and its relation to growth. Int J Cancer. 74:1997;180-184.
24. Weber R G, Collins V P, Bostrom J. Analysis of genomic alterations in benign, atypical and anaplastic meningiomas: towards a genetic model of meningioma progression. Proc Natl Acad Sci USA. 94:1997;14719-14724.